Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of targetable vulnerabilities of PLK1-overexpressing cancers by synthetic dosage lethality

9 May 2025

Abstract excerpt

Chromosomal instability (CIN) drives tumor heterogeneity, complicating cancer therapy. Although Polo-like kinase 1 (PLK1) overexpression induces CIN, direct inhibition of PLK1 has shown limited clinical benefits. We therefore performed a genome-wide synthetic dosage lethality (SDL) screen to identify effective alternative targets and validated over 100 candidates using in vivo and in vitro secondary CRISPR...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to DNA Repair Mechanisms
Share to Microtubule and mitosis dynamics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40347943
DOI: 10.1016/j.xgen.2025.100876

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of targetable vulnerabilities of PLK1-overexpressing cancers by synthetic dosage lethalityPMID 40347943Read ↗

Identification of targetable vulnerabilities of PLK1-overexpressing cancers by synthetic dosage lethalitySemantic proximity Read ↗

Therapeutic relevance of the protein phosphatase 2A in cancer.Semantic proximity Read ↗

The CINs of Polo-Like Kinase 1 in CancerSemantic proximity Read ↗

CRISPR-enabled genetic screens identify synthetic lethal targets across frequently altered cancer driversSemantic proximity Read ↗

Pharmacogenomic discovery of genetically targeted cancer therapies optimized against clinical outcomesSemantic proximity Read ↗

A synthetic lethal dependency on casein kinase 2 in response to replication-perturbing therapeutics in RB1-deficient cancer cellsSemantic proximity Read ↗

Polo-like Kinase 1 Inhibition as a Therapeutic Approach to Selectively Target BRCA1-Deficient Cancer Cells by Synthetic Lethality InductionSemantic proximity Read ↗

Whole genome doubling confers unique genetic vulnerabilities on tumor cellsSemantic proximity Read ↗

The biological essence of synthetic lethality: Bringing new opportunities for cancer therapySemantic proximity Read ↗

A Synthetic Dosage Lethal Genetic Interaction Between CKS1B and PLK1 Is Conserved in Yeast and Human Cancer CellsSemantic proximity Read ↗

Uncovering cancer vulnerabilities by machine learning prediction of synthetic lethality.Semantic proximity Read ↗

Synthetic Lethality in Cancer Therapeutics: The Next GenerationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.